Clinical Trial Update: Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma [NA]

View source ↗

Summary

A completed clinical trial evaluating macrophage-colony stimulating factor as a biomarker for bone lesions in patients with multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Multiple Myeloma | NA | Status: COMPLETED